Truist lowered the firm’s price target on AdaptHealth (AHCO) to $13 from $14 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
- AdaptHealth’s Strategic Divestitures and Strong Financial Performance Justify Buy Rating
- AdaptHealth’s Growth Potential and Resilience Justify Buy Rating Amid Promising Segment Performances and Minimal Tariff Impact
- AdaptHealth Reports Q1 2025 Financial Results
- AdaptHealth’s Mixed Earnings Call Highlights Progress and Challenges
- AdaptHealth reports Q1 EPS (5c), consensus 4c